



## **Long COVID Is Not One Thing: Why Clear Definitions Matter for Care, Research, and Patient Safety**

---

Long COVID is not a single condition. It is a label used to describe a wide range of health problems that can persist after COVID-19 infection. Treating this broad category as one illness creates real problems for patient care, clinical decision-making, and research clarity.

Major health organizations often define Long COVID broadly as new, ongoing, or relapsing health issues following infection. This is intentional. Broad definitions support public awareness, policy discussions, funding, and access to care. However, they also blur important differences in symptoms, underlying physiology, and appropriate treatment.

In reality, what is often referred to as “Long COVID” includes at least three different clinical realities, which may overlap:

1. Lasting organ or tissue damage related to the infection (heart, lungs, blood vessels, etc.)
2. A prolonged or relapsing recovery time from the infection itself
3. The development of a chronic post-viral illness (such as ME/CFS or an ME-like illness)

### **Why this Matters**

When these different health impacts are treated as one condition, both care quality and research precision are compromised.

In clinical care, applying the same approach to all patients can ignore critical differences in symptom patterns and introduce inappropriate, or even harmful, treatments. For example, exercise-based rehabilitation may support recovery in some patients with organ damage, while causing significant and lasting deterioration in patients with post-viral illness involving post-exertional malaise (PEM).

In research, grouping all patients together can lead to protocols that are inappropriate for



-2-

certain patient sub-groups. It can also distort findings: a treatment may appear modestly beneficial overall while actually helping one group, having no effect in another, and harming a third. This can lead to protocols that are unsafe for some participants, and to conclusions that understate benefits, obscure harms, and are difficult to apply in practice.

### **Moving Forward**

“Long COVID” remains a useful umbrella term for recognition, public awareness, policy development, and access to care. It is not sufficient for guiding effective treatment or impactful research design.

In clinical care, the focus must move beyond the “Long COVID” label and toward identifying the unique pattern of symptoms and physiological effects each patient is experiencing.

In research, clearer definition and description of patient populations is essential. Without this, protocols may be inappropriate for some sub-groups, and results may be diluted, misleading, or unsafe to generalize.

Understanding how COVID-19 affects the body over the long term is not a semantic issue. It is central to safe and effective care, meaningful research, and improved outcomes for patients.

### **References and Related Literature**

#### **Broad Definitions of Long COVID/Post-COVID Conditions**

World Health Organization (WHO) defines post-COVID-19 condition as symptoms occurring within 3 months of infection, lasting at least 2 months, and not explained by another diagnosis. Emphasizes broad, multisystem impact.

[https://www.who.int/news-room/fact-sheets/detail/post-covid-19-condition-\(long-covid\)](https://www.who.int/news-room/fact-sheets/detail/post-covid-19-condition-(long-covid))



-3-

Centers for Disease Control and Prevention (CDC) define Long COVID as a chronic condition present at least 3 months after infection, with a wide range of ongoing or new symptoms. <https://www.cdc.gov/long-covid/about/index.html>

National Academies of Sciences, Engineering, and Medicine (NASEM) define Long COVID as an infection-associated chronic condition that can affect one or more organ systems. <https://www.nationalacademies.org/publications/27768>

National Institute for Health and Care Excellence (NICE) uses 'long-term effects of COVID-19' as an umbrella for ongoing symptomatic COVID-19 and post-COVID-19 syndrome. <https://www.nice.org.uk/guidance/ng188>

### **Selected Literature Regarding Long-Term Effects of COVID 19**

Jason, L.A., et al. (2022). ME/CFS and Post-Exertional Malaise among Patients with Long COVID. <https://pubmed.ncbi.nlm.nih.gov/36648965/>

NIH RECOVER Initiative (2023). ME/CFS and PEM in Long COVID. <https://recovercovid.org/publications/mecfs-and-post-exertional-malaise-among-patients-long-covid>

Davis, H.E., et al. (2023). Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. <https://www.nature.com/articles/s41579-022-00846-2>

New England Journal of Medicine (2024). Long Covid Defined. <https://www.nejm.org/doi/full/10.1056/NEJMSb2408466>

Bierle, D.M., et al. (2021). Central Sensitization Phenotypes in Post-Acute Sequelae of SARS-CoV-2 Infection. <https://pubmed.ncbi.nlm.nih.gov/34231404/>